Veristat Expands Biometrics Capabilities by Acquiring SQN Clinical

Feb 25, 2021

Builds on a shared pedigree of data management, statistics and programming excellence across all phases of clinical trialsBuilds on a shared pedigree of data management, statistics and programming excellence across all phases of clinical trials

Posted by Veristat, LLC

SOUTHBOROUGH, MA – 25 February 2021 – Veristat, a scientific-minded, global clinical research organization (CRO), announced today the expansion of its biometrics capacities and European team by acquiring SQN Clinical, market-leader in the healthcare arena and one of the largest datafocused specialty contract research companies in Europe. For 25 years, SQN Clinical has successfully supported the needs of global pharmaceutical, biotechnology, medical device, and animal health partners. SQN Clinical’s innovative clinical development capabilities include a full spectrum of trial, data, and project management solutions powered by robust statistical analysis and reporting. The acquisition adds more than 100 professionalsincreasing Veristat’s European footprint and bolstering one of Veristat’s most sought after service areas, solidifying its position as a premier provider of world class biometrics solutions. 


Veristat’s growth has been propelled by our ability to offer our customers specialized solutions that accelerate their success,” stated Patrick Flanagan, Chief Executive Officer for Veristat. “The acquisition of SQN Clinical demonstrates our global commitment to those services that play a formative role in driving clinical development and commercial success. We have a tremendous opportunity to deliver flexible approaches with local support to tackle even the most complex clinical data challenges— a win for sponsors and patients alike.”  


The evolving complexities of regulations— in the European region in particular— bring about a unique set of challenges that impact how clinical data is managed and governed. SQN Clinical’s high calibre team, coupled with Veristat’s robust end-to-end clinical development and regulatory submission capabilities, provide clients with a trusted resource bringing the right people, processes, and technology together to glean the most value from clinical data and move trials successfully forward. 


“The joining of our organizations enables Veristat to address the needs of our European and global customers conducting trials in the US, UK and throughout Europe,” commented Montse Barceló Riera, M.D., Vice President, Europe for Veristat. SQN Clinical enhances Veristat’s biometrics capabilities across the continent to proactively address the increased demand from sponsors.” 

SQN Clinical has established a ‘customer-first’ reputation by providing highquality, on time, on budget expertise working as an extension of a sponsor’s team. Enriching analytical insight and working as a true partner with our clients to reduce the time and cost burdens of clinical trials and improve their results has always been a foundational goal,” stated Karen Grover, Director of SQN Clinical. “We have a shared reputation for scientific excellence and a shared passion for teamwork to support consistent service delivery and the highest quality outcomes.”  




See all Member News